Serge Cremers, PhD, PharmD

Accepting New Patients
Profile Headshot

Profile Navigation


Areas of Expertise / Conditions Treated

Pharmacology, Clinical Chemistry

Academic Appointments

  • Associate Professor of Pathology & Cell Biology at CUMC

Serge Cremers was born in 1969 in Heerlen, The Netherlands. He received his PharmD from the University of Groningen in 1996 and his PhD from Leiden University in The Netherlands in 2004. He joined Columbia University in 2006 after working for 2 years as a Clinical Pharmacologist at Novartis Oncology in Florham Park, NJ. He is currently an Associate Professor of Pathology & Cell Biology and Medicine at CUMC, where he is also an attending Clinical Chemist. He is director of Pathology's Clinical Pharmacology and Toxicology Laboratory as well as director of the Biomarkers Core Laboratory of the Irving Institute for Clinical and Translational Research. Dr Cremers' research focuses on clinical and translational pharmacology of drugs in cancer, transplantation, contraception and metabolic bone diseases. He has (co-)authored over 100 original papers and a number or reviews and book chapters. He is also Senior Editor (Reviews) of the British Journal of Clinical Pharmacology.



  • Dutch
  • French
  • Greek


  • Male


Selected Publications

A. Original, Peer-reviewed articles:

1. Dutta A, Panja S, Virk RK, Kim JY, Zott R, Cremers S, Golombos DM, Liu D, Mosquera JM, Mostaghel EA, Barbieri CE, Mitrofanova A, and Abate-Shen C.  Co-clinical analysis of a genetically-engineered mouse model and human prostate cancer reveals significance of NKX3.1 expression for response to 5-alpha-reductase inhibition. Eur Urology 2017; in press.  

2. Welsch ME, Kaplan A, Chambers JM, Stokes ME, Bos PH, Zask A, Zhang Y, Sanchez-Martin M, Badgley MA, Huang CS, Tran TH, Akkiraju H, Brown LM, Nandakumar R, Cremers S, Yang WS, Tong L, Olive KP, Ferrando A, Stockwell BR. Multivalent Small-Molecule Pan-RAS Inhibitors. Cell. 2017;168(5):878-889

3. Praditpan P, Hamouie A, Basaraba CN, Nandakumar R, Cremers S, Davis AR, Westhoff CL. Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception. 2017, In Press.

4. Westhoff CL, Pike MC, Cremers S, Eisenberger A, Thomassen S, Rosing J. Endogenous thrombin potential changes during the first cycle of oral contraceptive use. Contraception. 2017, In Press.

5. Basaraba CN, Westhoff CL, Pike MC, Nandakumar R, Cremers S. Estimating systemic exposure to levonorgestrel from an oral contraceptive. Contraception. 2016, In Press.

6. Amengual JE, Prabhu SA, Lombardo M, Zullo KM, Johannet PM, Gonzalez Y, Scotto L, Jirau-Serrano X, Wei Y, Duong JK, Nandakumar R, Cremers S, Verma A, Elemento O, O'Connor OA. Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug : Drug Combination with Ibrutinib. Clin Cancer Res. 2016, in Press.

7. Carrelli A, Bucovsky M, Horst R, Cremers S, Zhang C, Bessler M, Schrope B, Evanko J, Blanco J, Silverberg SJ, Stein EM. Vitamin D Storage in Adipose Tissue of Obese and Normal Weight Women. J Bone Miner Res. 2016, In Press.

8. Cheslack-Postava K, Cremers S, Bao Y, Shen L, Schaefer CA, Brown AS. Maternal serum cytokine levels and risk of bipolar disorder. Brain Behav Immun. 2016, In Press.

9. Greenlee H, Odgen Gaffney A, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Shi Z, Lim E, Tsai WY, Santella RM, Blaner WS, Clugston RD, Cremers S, Pollak S, Sirosh I, Crew KD, Maurer M, Kalinsky K, Hershman DL. Long-term diet and biomarker changes after a short-term intervention among Hispanic breast cancer survivors: The ‘Cocinar Para Su Salud’ randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2016;25(11):1491-1502.

10. Saland JM, Satlin LM, Zalsos-Johnson J, Cremers S, Ginsberg HN. Impaired postprandial lipemic response in chronic kidney disease. Kidney Int. 2016; 90(1):172-80.

11. Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG, Cremers S, Dworakowski E, Bilezikian JP. Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab. 2016;101(7):2742-50.

12. Kancheva Landolt N, Bunupuradah T, Kosalaraksa P, Ubolyam S, Thammajaruk N, Cremers S, Zott R, Kerr S, Ananworanich J; HIV-NAT 176 study. High variability of hormonal levels and no clinically relevant interaction between ethinyl estradiol, desogestrel and lopinavir/ritonavir in a small sample of HIV-positive adolescents. J Acquir Immune Defic Syndr. 2016; 72(5):507-12.

13. Alsahli A, Kiefhaber K, Gold T, Muluke M, Jiang H, Cremers S, Schulze-Späte U. Palmitic Acid Reduces Circulating Bone Formation Markers in Obese Animals and Impairs Osteoblast Activity via C16-Ceramide Accumulation. Calcif Tissue Int. 2016; 98(5):511-9.

14. Morrell KM, Cremers S, Westhoff CL, Davis AR. Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year. Contraception. 2016; 93(3):263-5.

15. Westhoff CL, Eisenberger A, Tang R, Cremers S, Grossman LV, Pike MC. Clotting factor changes during the first cycle of oral contraceptive use. Contraception. 2016;93(1):70-6.

16. Muluke M, Gold T, Kiefhaber K, Al-Sahli A, Celenti R, Jiang H, Cremers S, Van Dyke T, Schulze-Späte U. Diet-Induced Obesity and Its Differential Impact on Periodontal Bone Loss. J Dent Res. 2016;95(2):223-9.

17. Cohen A, Kamanda-Kosseh M, Recker RR, Lappe JM, Dempster DW, Zhou H, Cremers S, Bucovsky M, Stubby J, Shane E. Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis. J Clin Endocrinol Metab. 2015;100(11):4208-14.

18. Amengual JE, Johannet PM, Lombardo M, Zullo KM, Hoehn D, Bhagat G, Scotto L, Jirau-Serrano X, Radeski D, Heinen J, Jiang H, Cremers S, Zhang Y, Jones SS, O'Connor OA. Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor, ACY-1215, and bortezomib is synergistic in lymphoma. Clin Cancer Res. 2015;21(20):4663-75.

19. Ozcan L, Xu X, Deng SX, Ghorphade DS, Thomas T, Cremers S, Hubbard B, Serrano-Wu MH, Gaestel M, Landry DW, Tabas I. Treatment of Obese Insulin-Resistant Mice with an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity.Diabetes. 2015;64(10):3396-405.

20. Zullo KM, Guo Y, Cooke LS, Jirau-Serrano X, Mangone M, Scotto L, Amengual JE, Mao Y, Nandakumar R, Cremers S, Duong J, Mahadevan D, O'Connor OA. Aurora A Kinase Inhibition Selectively Synergizes With Histone Deactylase Inhibitor Through Cytokinesis Failure In T-Cell Lymphoma. Clin Cancer Res. 2015; 15;21(18):4097-109.

21. Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O'Connor OA. Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. Clin Cancer Res. 2015;21(9):2096-106.

22. Rubin MR, Goldfine AB, McMahon DJ, Donovan DS, Cremers S, Dworakowski E, Schaefer EJ, Shoelson SE, Silverberg SJ. Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus. Endocrine. 2015, In Press.

23. Westhoff CL, Pike MC, Tang R, DiNapoli MN, Sull M, Cremers S. Estimating systemic exposure to ethinyl estradiol from an oral contraceptive. Am J Obstet Gynecol. 2015; 212(5):614.e1-7.

24. Reimers LL, Crew KD, Bradshaw PT, Santella RM, Steck SE, Sirosh I, Terry MB, Hershman DL, Shane E, Cremers S, Dworakowski E, Teitelbaum SL, Neugut AI, Gammon MD. Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk. Cancer Causes Control. 2015 Feb;26(2):187-203.

25. Yoshida K, Jiang H, Kim M, Vink J, Cremers S, Paik D, Wapner R, Mahendroo M, Myers K. Quantitative evaluation of collagen crosslinks and corresponding tensile mechanical properties in mouse cervical tissue during normal pregnancy. PLoS One. 2014;14;9(11):e112391.

26. Lau YK, Du X, Rayannavar V, Hopkins B, Shaw J, Bessler E, Thomas T, Pires MM, Keniry M, Parsons RE, Cremers S, Szabolcs M, Maurer MA. Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget. 2014; 15;5(21):10503-17.

27. Zork NM, Myers KM, Yoshida K, Cremers S, Jiang H, Ananth CV, Wapner RJ, Kitajewski J, Vink J. A systematic evaluation of collagen cross-links in the human cervix. Am J Obstet Gynecol. 2015;212(3):321.e1-8.

28. Claassen J, Albers D, Schmidt JM, Demarchis GM, Pugin D, Falo CM, Mayer SA, Cremers S, Agarwal S, Elkind MS, Connolly ES, Dukic V, Hripcsak G, Badjatia N. Nonconvulsive seizures in subarachnoid hemorrhage link Inflammation and outcome. Ann Neurol. 2014;75(5):771-81.

29. Beasley A, White KO, Cremers S, Westhoff C. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate. Contraception. 2014;89(5):352-6.

30. Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kerr S, Ahluwalia J, Thongpaeng P, Thammajaruk N, Cremers S, Thomas T, Chaithongwongwatthana S, Lange JM, Ananworanich J. Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women. J Acquir Immune Defic Syndr. 2014;66(2):e50-2.

31. Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, Taback B, Ahmad A, Cremers S, Hibshoosh H, Maurer M, Hershman DL. Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer. Cancer Invest. 2014;32(4):150-7.

32. Costa AG, Cremers S, Dworakowski E, Lazaretti-Castro M, Bilezikian JP. Comparison of two commercially available ELISAs for circulating sclerostin. Osteoporos Int. 2014;25(5):1547-54.

33. Iyer SP, Nikkel LE, Nishiyama KK, Dworakowski E, Cremers S, Zhang C, McMahon DJ, Boutroy S, Liu XS, Ratner LE, Cohen DJ, Guo XE, Shane E, Nickolas TL. Kidney Transplantation with Early Corticosteroid Withdrawal: Paradoxical Effects at the Central and Peripheral Skeleton. J Am Soc Nephrol. 2014;25(6):1331-41.

34. Yoshida K, Reeves C, Vink J, Kitajewski J, Wapner R, Jiang H, Cremers S, Myers K. Cervical Collagen Network Remodeling in Normal Pregnancy and Disrupted Parturition in Antxr2 Deficient Mice. J Biomech Eng. 2014;136(2):021017.

35. Henrich PP, O'Brien C, Sáenz FE, Cremers S, Kyle DE, Fidock DA. Evidence for Pyronaridine as a Highly Effective Partner Drug for the Treatment of Artemisinin-Resistant Malaria in a Rodent Model. Antimicrob Agents Chemother. 2014;58(1):183-95.

36. Langers P, Press RR, Inderson A, Cremers SC, den Hartigh J, Baranski AG, van Hoek B. Limited Sampling Model for Advanced Mycophenolic Acid Therapeutic Drug Monitoring After Liver Transplantation. Ther Drug Monit. 2014;36(2):141-7.

37. Costa AG, Walker MD, Zhang CA, Cremers S, Dworakowski E, McMahon DJ, Liu G, Bilezikian JP. Circulating Sclerostin Levels and Markers of Bone Turnover in Chinese-American and White Women. J Clin Endocrinol Metab. 2013;98(12):4736-43.

38. Thomas T, Petrie K, Shim J, Abildskov KM, Westhoff CL, Cremers S. A UPLC-MS/MS method for therapeutic drug monitoring of etonogestrel. Ther Drug Monit 2013; 35(6):844-8.

39. Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, Bauer DC, Orwoll ES, Bilezikian JP. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based non-referral populations. J Clin Endocrinol Metab 2013;98(7):2734-41.

40. Cohen A, Stein EM, Recker RR, Lappe JM, Dempster DW, Zhou H, Cremers S, McMahon DJ, Nickolas TL, Müller R, Zwahlen A, Young P, Stubby J, Shane E. Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Pilot Study. J Clin Endocrinol Metab 2013; 98(5):1971-81.

41. Silva BC, Boutroy S, Zhang C, McMahon DJ, Zhou B, Wang J, Udesky J, Cremers S, Sarquis M, Guo XD, Hans D, Bilezikian JP. Trabecular Bone Score (TBS)--A Novel Method to Evaluate Bone Microarchitectural Texture in Patients with Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2013;98(5):1963-70.

42. Cohen A, Dempster DW, Recker RR, Lappe JM, Zhou H, Zwahlen A, Müller R, Zhao B, Guo X, Lang T, Saeed I, Liu XS, Guo XE, Cremers S, Rosen CJ, Stein EM, Nickolas TL, McMahon DJ, Young P, Shane E. Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab. 2013;98(6):2562-72.

43. Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, McMahon DJ, Liu XS, Boutroy S, Cremers S, Shane E. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res. 2013;28(8):1811-20.

44. Leaf DE, Waikar SS, Wolf M, Cremers S, Bhan I, Stern L. Dysregulated Mineral Metabolism in Patients with Acute Kidney Injury and Risk of Adverse Outcomes. Clin Endocrinol (Oxf). 2013;79(4):491-8.

45. Stein EM, Silva BC, Boutroy S, Zhou B, Wang J, Udesky J, Zhang C, McMahon DJ, Romano M, Dworakowski E, Costa AG, Cusano N, Irani D, Cremers S, Shane E, Guo XE, Bilezikian JP. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res 2012;28(5):1029-40.

46. Dragoman M, Petrie K, Torgal A, Thomas T, Cremers S, Westhoff CL. Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women. Contraception. 2013;87(4):432-6.

47. Gautier EL, Westerterp M, Bhagwat N, Cremers S, Shih A, Abdel-Wahab O, Lütjohann D, Randolph GJ, Levine RL, Tall AR, Yvan-Charvet L. HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med. 2013;210(2):339-53.

48. Westhoff CL, Torgal AH, Mayeda ER, Petrie K, Thomas T, Dragoman MV, Cremers S. Using Changes in Binding Globulins to Assess OCP Compliance. Contraception 2013; 87(2):176-81.

49. Cusano NE, Rubin MR, McMahon DJ, Zhang C, Ives R, Tulley A, Sliney Jr. J, Cremers S, Bilezikian JP. Therapy of Hypoparathyroidism with PTH(1-84): A Prospective Four Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab. 2013;98(1):137-44.

50. Tsapepas D, Saal S, Benkert S, Levine D, Delfin M, Cremers S, Amann S, Dadhania D, Kapur S, Aull M. Sublingual Tacrolimus – A Detailed Pharmacokinetic Evaluation Pilot Study. Pharmacotherapy 2013;33(1):31-7.

51. Westerterp M, Gourion-Arsiquaud S, Murphy AJ, Shih A, Cremers S, Levine RL, Tall AR, Yvan-Charvet L. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell. 2012;11(2):195-206.

52. Wu C, Kato TS, Pronschinske K, Qiu S, Naka Y, Takayama H, Schulze-Späte U, Cremers S, Shane E, Mancini D, Schulze PC. Dynamics of bone turnover markers in patients with heart failure and following haemodynamic improvement through ventricular assist device implantation. Eur J Heart Fail. 2012;14(12):1356-65.

53. Westhoff CL, Torgal AH, Mayeda ER, Petrie K, Thomas T, Dragoman MV, Cremers S. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal weight and obese women. J Obstet Gynecol 2012; 207(1):39.e1-6.

54. Thomas TA, Broun EC, Abildskov KM, Kubin CJ, Horan J, Yin MT,  Cremers S. High Performance Liquid Chromatography-Mass Spectrometry (LC-MS) assay for polymyxin B1 and B2 in human plasma. Ther Drug Monit 2012; 34(4):398-405.

55. Gautier EL, Cremers S, Dempster DW, Lütjohann D, Randolph GJ, Tall AR, Yvan-Charvet L. High glycolytic rate in ABCA1 and ABCG1 deficient leukocytes links myeloproliferative disorder to adipose tissue cachexia. Cell Stem Cell 2012; 3;11(2):195-206.

56. Leaf DE, Wolf M, Waikar SS, Chase H, Cremers S, Stern L. FGF-23 levels in patients with acute kidney injury and risk of adverse outcomes. Clin J Am Soc Nephr 2012, 7(8):1217-23.

57. Curtis JR, Ewing SK, Bauer DC, Cauley JA, Cawthon PM, Barrett-Connor E, Haney EM, Ishani A, Cremers S, Orwoll E. Association of Intact Parathyroid Hormone Levels with Subsequent Hip BMD Loss: The Osteoporotic Fractures in Men (MrOS) Study. J Clin Endocrinol Metab. 2012;97(6):1937-44.

58. Manavalan JS, Cremers S, Dempster DW, Zhou H, Dworakowski E, Kode A, Kousteni S, Rubin MR. Circulating Osteogenic Precursor Cells in Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2012; 97(9):3240-50.

59. Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, Patil S, Fleisher M, Cremers S, Huryn J, Hudis CA, Fornier MN. Serum N-Telopeptide and Bone-Specific Alkaline Phosphatase Levels in Patients With Osteonecrosis of the Jaw Receiving Bisphosphonates for Bone Metastases. J Oral Maxillofac Surg. 2012;70(12):2768-75.

60. Kelley JM, Melanson SEF, Snyder ML, Cremers S, Jarolim P. Method Comparison of a 25-Hydroxy Vitamin D Enzyme Immunoassay to Liquid Chromatography Tandem Mass Spectroscopy. Clinical Chemistry and Laboratory Medicine 2012; 50(6):1137-8.

61. Yin MT, Zhang CA, McMahon DJ, Ferris DC, Irani D, Colon I, Cremers S, Shane E. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab 2011; 97(2):554-62.

62. Cohen A, Dempster DW, Recker RR, Stein EM, Lappe JM, Zhou H, Wirth AJ, van Lenthe GH, Kohler T, Zwahlen A, Müller R, Rosen CJ, Cremers S, Nickolas TL, McMahon DJ, Rogers H, Staron RB, Lemaster J, Shane E. Abnormal Bone Microarchitecture and Evidence of Osteoblast Dysfunction in Premenopausal Women with Idiopathic Osteoporosis. J Clin Endocrinol Metab. 2011, 96(10):3095-3105.

63. Rubin M, Dempster D, Sliney J, Zhou H, Nickolas T, Stein E, Dworakowski E, Dellabadia M, Ives R, McMahon D, Zhang C, Silverberg S, Shane E, Cremers S, Bilezikian JP. PTH(1-84) Administration Reverses Abnormal Bone Remodeling Dynamics and Structure in Hypoparathyroidism. J Bone Mineral Res 2011, 26(11):2727-2736.

64. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney J, Lazaretti-Castro M, Silverberg SJ, Bilezikian JP. Circulating sclerostin in disorders of the parathyroid gland function. J Clin Endocrinol Metab 2011, 96(12):3804-3810.

65. Nickolas T, Cremers S, Zhang A, Stein EM,  Cohen A, Chauncey R, Nikkel L, Liu X, Boutroy S, Yin M, Staron M, Leonard M, McMahon D, Dworakowski E, Shane E. Discriminants of prevalent fractures in chronic kidney disease. J Am Soc Nephrol 2011, 22(8):1560-72.

66. Cozin M, Pinker BM, Solemani K, Zuniga JM, Dadaian SC, Cremers S, Landesberg R, Raghavan S. Novel Therapy to Reverse the Cellular Effects of Bisphosphonates on  Primary Human Oral Fibroblasts. J Oral Maxillofac Surg 2011; 69(10):2564-2578.

67. Marolt D, Cozin M, Vunjak-Novakovic G, Cremers S, Landesberg R. Effects of Pamidronate on Human Alveolar Osteoblasts In Vitro. J Oral Maxillofac Surg 2012; 70(5):1081-92.

68. Shu A, Yin MT, Stein E, Cremers S, Dworakowski E, Ives R, Rubin MR. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int. 2012; 23(2):635-41.

69. Cohen A, Recker RR, Lappe J, Dempster DW, Cremers S, Stein EM, Rosen CJ, Rogers H, Staron RB, LeMaster J, Shane E. Premenopausal Women with Idiopathic Low Trauma Fractures and/or Low Bone Mineral   Density. Osteoporos Int. 2012; 23(1):171-82.

70. Yadav VK, Oury F, Tanaka K, Thomas T, Wang Y, Cremers S, Schutz G, Hen R, Krust A, Chambon P, Karsenty G. Leptin-dependent serotonin control of appetite: temporal specificity, transcriptional mediation and therapeutic implications. J Exp Med  2011;208(1):41-52.

71. Rubin MR, Manavalan JS, Dempster DW, Shah J, Cremers S, Kousteni S, Zhou H, McMahon DJ, Kode A, Sliney J, Shane E, Silverberg SJ, Bilezikian JP. Parathyroid Hormone Stimulates Circulating Osteogenic Cells in Hypoparathyroidism. J Clin Endocrinol Metab. 2011;96(1):176-186.

72. Yin MT, Modarresi R, Shane E, Santiago F, Ferris DC, McMahon DJ, Zhang CA, Cremers S, Laurence J. Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women. Osteoporos Int. 2011;22(5):1549-1568.

73. Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, Awad D, Shane E. Prevention of Bone Loss by Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist up to One Year following Discontinuing Treatment. J Clin Endocrinol Metab. 2010; 95(2):559-66.

74. Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, Shi Q, Shane E, Golub ET, Anastos K. Short-Term Bone Loss in HIV-Infected Premenopausal Women. J Acquir Immune Defic Syndr. 2010; 1;53(2):202-8.

75. Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, Shane E, Terry MB, Desai M, Teitelbaum SL, Neugut AI, Santella RM. Association between Plasma 25-Hydroxyvitamin D and Breast Cancer Risk. Cancer Prev Res 2009; 2(6):598-604.

76. Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Sierra A, Hershman DL. High Prevalence of Vitamin D Deficiency in a Multi-Ethnic Cohort of Premenopausal Breast Cancer Patients at Diagnosis, During Adjuvant Chemotherapy, and After One Year of Vitamin D Supplementation. J Clin Oncol; 2009;27(13):2151-6.

77. Langers P, Press RR, den Hartigh J, Cremers S, Baranski AG, Lamers CBHW, Hommes DW, van Hoek B. Flexible limited sampling model for monitoring tacrolimus after orthotopic liver transplantation with sample 4-6 hours after dosing is superior to C0. Ther Drug Monit 2008; 30(4):456-61.

78. Hershman DL, MacMahon D, Crew KD, Cremers S, Irani G, Brafman L, Shane E. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early stage breast cancer. J Clin Oncol 2008;26(29):4739-45.

79. Willemze AJ, Cremers SC, Schoemaker RC, Lankester AC, den Hartigh J, Burggraaf J, Vossen JM. Ciclosporin kinetics in children after stem cell transplantation. British Journal of Clinical Pharmacology 2008; 66(4):539-45.

80. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66(5):839-847.

81. Spencer A, Roberts A, Kennedy N, Ravera C, Cremers S, Bilic S, Neeman T, Copeman M, Schran H, Lynch K. Renal safety of zoledronic acid with thalidomide in patients with multiple myeloma: a pharmacokinetic and safety sub-study. BMC Clin Pharmacol 2008;31:8:2:1-4.

82. Papapoulos SE, Cremers SCLM. Bisphosphonate is released in the circulation for at least 8 years after cessation of long-term treatment of children with osteoporosis. N Engl J Med 2007;356:1075-1076.

83. Langers P, Cremers S, den Hartigh J, Rijnbeek EM, Ringers J, Lamers CB, Hommes DW, van Hoek B. Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice. Aliment Pharmacol Ther 2007; 26(10):1447-54.

84. Scholten EM, Rowshani AT, Cremers S, Bemelman F, Eikman M, van Kan E, Mallat M, Florquin S, Surachno J, ten Berge I, Bajema IM, de Fijter JW. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am Soc Nephrol 2006; 17:2622-2632.

85.  Langers P, Cremers SCLM, den hartigh J, Rijnbeek EMT, Ringers J, Lamers CBHW, van Hoek B. A novel, easy-to-use, accurate and flexible limited sampling method without fixed time points based on population- as well as individual pharmacokinetic data for ciclosporin monitoring to avoid over- or underdosing after liver transplantation. Aliment Pharmacol Ther 2005; 21:549-557.

86.  Scholten EM, Cremers SCLM, Schoemaker R, Rowsjani AT, van Kan E, den Hartigh J, Paul LC, de Fijter JW. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney International, 2005; 67:2440-2447.

87. Cremers SCLM, Schoemaker R, Scholten E, den Hartigh J, de Fijter J. Characterizing the interaction between mycophenolic acid and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacology 2005; 60(3):249-256.

88.  Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, Cox MC, Zhai S, Cremers SCLM, Parr A, Yang X, Chen C, Jones E, Dahut W. A randomized phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen-independent prostate cancer and bone metastases. J Urology  2005; 179:790-796.

89. Cremers SCLM, van Hogezand R, Bänffer D, den Hartigh J, Vermeij P, Papapoulos SE, Hamdy NAT. Absorption of oral bisphosphonate (alendronate) and rate of bone turnover in patients with Crohn's disease. Osteoporosis Int 2005; 16:1727-1730.

90.  Cremers SCLM, van Zuylen C, Gelderblom J, Seynaeve C, den Hartigh J, Pols H, Vermeij P, van der Rijt CCD, Papapoulos SE. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Mineral Res 2005; 20(9):1543-1547.

91. Zwaveling J, Bredius RGM, Cremers SCLM, Ball LM, Lankester AC, Teepe-Twiss IM, Egeler RM, den Hartigh J, Vossen JM. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplantation 2005; 35(1):17-23.

92. Cremers SCLM, Lodder MC, den Hartigh J, Vermeij P, van Pelt PA, Lems WF, Papaoulos SE, Dijkmans BAC. Short-term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis. J Rheumatology 2004; 31(9):1732-1737.

93. Langers P, Cremers SCLM, den Hartigh J, Veenendaal RA, ten Hove R, Ringers J, Lamers CBHW, van Hoek B. Switching emulsified ciclosporin monitoring from trough level to 2-hour level monitoring in stable liver transplant patients: Effects on ciclosporin  dose, renal function , blood pressure, rejection, and relation to area under the curve. Liver Transplantation 2004; 10(2):183-189.

94. Eekhoff EMW, Zwinderman AH, Haverkort DMAD, Cremers SCLM, Hamdy NAT, Papapoulos SE. Determinants of induction and duration of Paget's disease of bone after bisphosphonate (olpadronate) therapy. Bone 2003; 33:831-838

95. Cremers SCLM, Eekhoff EMW, Den Hartigh J, Hamdy NAT, Vermeij P, and Papapoulos SE. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Mineral Res 2003; 18:868-875.

96. Cremers SCLM, Scholten EM, Schoemaker RC, Lentjes EGWM, Vermeij P, Paul LC, den Hartigh J, de Fijter JW. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrology Dialysis Transplantation 2003; 18:1201-1208.

97. Cremers SCLM, Schoemaker R, Bredius R, Den Hartigh J, Ball L, Twiss IM, Vermeij P, Vossen J. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. British Journal of Clinical Pharmacology 2002; 53:386-389.

98. Cremers SCLM, Sparidans RW, Den Hartigh J, Hamdy NAT, Vermeij P, and Papapoulos SE. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 2002; 57:883-890.

99. Sparidans RW, Den Hartigh J, Cremers SCLM, Beijnen JH, and Vermeij P. Semi-automatic liquid chromatographic analysis of olpadronate in urine and serum using derivatization with (9-fluorenylmethyl)chloroformate. J Chromatogr B 2000; 738:331-341.

100. Sparidans RW, Den Hartigh J, Cremers S, Beijnen JH, Vermeij P. Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphtylisothiocyanate. J Chromatogr B 1999; 730:95-99.

B. Reviews and Editorials:

1. Cremers S, Guha N, Shine B. Therapeutic drug monitoring in the era of precision medicine: opportunities! Br J Clin Pharmacol. 2016 Oct;82(4):900-2.

2. Cremers S. Efficacy of drugs in development for osteoporosis. Eur J Hosp Pharmacy, 2011;17(4):18-21.

3. Costa AG, Cusano N, Silva B, Cremers S, Bilezikian JP. Cathepsin K: a review of its skeletal actions and as a therapeutic target for the treatment of osteoporosis. Nature Rev Rheum 2011;7(8):447-456.

4. Cremers S, Papapoulos SE. Pharmacology of bisphosphonates. Bone 2011;49(1):42-49.

5. Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, Kousteni S, Raghavan S. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci. 2011 Feb;1218:62-79.

6. Cremers S, Farooki A. Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. Ann N Y Acad Sci. 2011;1218:80-87.

7. Drake MT, Cremers S. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. Mol Interv. 2010 Jun;10(3):141-52.

8. Post T, Cremers S, Kerbusch T, Danhoff M. Bone Physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin Pharmacokinetics 2010; 49(2):89-118.

9. Cremers S, Bilezikian JP, Garnero P. Biochemical markers of bone turnover – New aspects. Clinical Laboratory; 2008;54:457-466.

10. Cremers S, Garnero P. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease. Potential uses and pitfalls. Drugs; 2006;66(16):2031-2058.

11. Cremers S. Role of clinical pharmacology in rational choice and dose of bisphosphonates in metastatic bone disease. Eur J Hosp Pharm Pract 2006;12(6):65-68.

12. Cremers SCLM, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinetics 2005; 44(6):551-570.

C. Book Chapters:

1. Cremers S. Clinical Chemistry: Toxicology and Therapeutic Drug Monitoring. In: Columbia University’s American Board of Clinical Pathology Review Questions, 2015; Spitalnik S, Jhang J, Editors. Elseviers, Amsterdam.

2. Cremers S, Turk A, Sepulveda J. Clinical Chemistry: Endocrinology. In: Columbia University’s American Board of Clinical Pathology Review Questions, 2015; Spitalnik S, Jhang J, Editors. Elseviers, Amsterdam.

3. Pesce MA, Rai AJ, Sepulveda JL, Cremers S. Clinical Chemistry: Electrolytes, Blood Gases, Renal Function. In: Columbia University’s American Board of Clinical Pathology Review Questions, 2015; Spitalnik S, Jhang J, Editors. Elseviers, Amsterdam.

4. Cremers S, Meier C, Seibel MJ. Markers of Bone Remodeling and the Aging Skeleton. In: Osteoporosis in Men, 2nd Edition; 2009; Orwoll E, Bilezikian JP, VanderSchueren D, Editors. Academic Press, New York.

5. Cremers S,  Garnero P, Seibel MJ. Biochemical markers of bone turnover. In: Principles of Bone Biology, 3rd Edition; 2008; Bilezikian JP, Raisz L, Martin TJ, Editors. Academic Press, New York.